bpc-157 ulcerative colitis phase ii clinical trial Pentadecapeptide BPC 157, in Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing Clinical Trials | Gastroenterology
Description
BPC-157: approximately 30 minutes (plasma)
But through prayer, stem cells, peptides, hyperbaric therapy, and unwavering faith, he defied the odds and made a full recovery
doi: 10.1177/0271678X17694185
So we use IV therapy to load our body up on NAD+ in a short amount of time, bypassing the limitations of oral NAD+ supplements
Longitudinal human work is scarce
